IRADIMED CORPORATION Reports Preliminary Unaudited Record Fourth Quarter and Full-Year 2024 Revenues

Core Insights - Iradimed Corporation reported preliminary unaudited revenue for Q4 and full-year 2024, indicating strong growth and record-breaking performance [2][3][7] - The company anticipates Q4 2024 revenue between $19.2 million and$19.4 million, reflecting a year-over-year growth of 10% to 11% and a sequential growth of 5% to 6% [2][7] - Full-year 2024 revenue is expected to be approximately $73.1 million to$73.3 million, compared to $65.6 million in the previous year, representing an 11% to 12% year-over-year growth [2][7] Financial Performance - Q4 2024 revenue is projected to be the highest quarterly revenue to date for the company, marking the 14th consecutive quarter of record revenues [3] - Orders booked in Q4 2024 exceeded shipments, resulting in a robust backlog and enhanced visibility for 2025 [3] Product Offerings - Iradimed is a leader in developing MRI-compatible medical devices, including the MRidium® MRI compatible IV infusion pump system and the 3880 MRI-compatible patient vital signs monitoring system [4][5][6] - The MRidium® system is designed to safely deliver anesthesia and IV fluids during MRI procedures, addressing safety concerns associated with standard infusion pumps [5] - The 3880 system allows for continuous monitoring of vital signs in high magnetic fields, enhancing patient safety and care during MRI scans [6] Upcoming Events - The company is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 5:15 p.m. Pacific Time [3][7]